Survey
Two Week Delay: Survey on GERN’s Rytelo (imetelstat) and MDS April 2025
Ticker(s): GERNThe survey includes 20 Hematologists/Oncologists.
How many lower risk MDS patients do you see?
How many patients have you prescribed Rytelo (imetelstat) to date?
What is your view on the overall profile of Rytelo (imetelstat)?
What profile of patient is a good candidate for Rytelo (imetelstat)?
Would you use Rytelo (imetelstat) before or after Reblozyl (luspatercept) in RS- patients?
- Before:
- After:
- Other:
What percentage (%) of patients who would otherwise be candidates for Rytelo (imetelstat) are unable to start due to a contraindication (baseline cytopenias, liver enzyme elevations, etc.)?
Anecdotally, how do your patients feel on Rytelo (imetelstat) compared to Reblozyl (luspatercept)?
What is the biggest barrier to using Rytelo (imetelstat)?
Please indicate the number of low-risk MDS patients (RS+) you currently have on each of the following treatments. Also, provide your projected patient counts for each treatment 1 year and 5 years from now.
- Now
- # on imetelstat
- # on luspatercept
- # on other therapies
- 1 year:
- # on imetelstat
- # on luspatercept
- # on other therapies
- 5 years:
- # on imetelstat
- # on luspatercept
- # on other therapies
Please indicate the number of low-risk MDS patients (RS-) you currently have on each of the following treatments. Also, provide your projected patient counts for each treatment 1 year and 5 years from now.
- Now
- # on imetelstat
- # on luspatercept
- # on other therapies
- 1 year:
- # on imetelstat
- # on luspatercept
- # on other therapies
- 5 years:
- # on imetelstat
- # on luspatercept
- # on other therapies
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
